Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2002

View Archived Issues

Johnson & Johnson to acquire all assets of Tibotec-Virco

New controlled release oral morphine product receives regulatory approval in Canada

Nobex and Pharmacia collaborate on oral protein drug delivery

Amrad ceases further development of emfilermin for chemotherapy-induced peripheral neuropathy

Aventis and Eisai to copromote Actonel in Japan

Phase I clinical trials of Genexol-PM commence in patients with refractory cancer

Calcium-sensing receptor modulators described in a recent CNRS patent

New antitumor compounds from marine sponge synthesized at the University of Barcelona

Ortho-McNeil claims new series of neuroprotective derivatives

Steroid derivatives useful for treating a number of neurodegenerative diseases identified at Kyorin

Angiotensin II antagonists jointly reported by Asahi Glass and Mitsubishi Pharma

ProusNet Channel 1 presents Orphan G-Protein Coupled Receptors

European Commission grants marketing approval for Arixtra

Dynepo receives E.U. approval for anemia of renal failure

Cellegy commences phase II/III trial of Tostrelle for treatment of FSD

ISTA reports preliminary phase III results for Vitrase

Keiten marketing rights transfer from Chugai to Fujisawa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...